About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
American Oriental Bioengineering, Inc. and Subsidiaries Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) THREE MONTHS ENDED NINE MONTHS ENDED SEPTEMBER 30, SEPTEMBER 30, 2009 2008 2009 2008 As Restated As Restated REVENUES $78,818,666 $70,593,949 196,117,893 $168,372,552 COST OF GOODS SOLD 34,687,505 23,402,407 81,942,766 54,808,490 GROSS PROFIT 44,131,161 47,191,542 114,175,127 113,564,062 Selling and marketing 12,245,746 9,938,877 26,853,377 22,656,
|SOURCE American Oriental Bioengineering, Inc.|
Copyright©2009 PR Newswire.
All rights reserved